Guillaume Millette

Mr. Guillaume Millette

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Viruses
Verified
Journal Article
Open access
PDF file
EBEric Brouillette
Eric Brouillette
GMGuillaume Millette
Guillaume Millette
SCSuzanne Chamberland
Suzanne Chamberland
JRJean-Pierre Roy
Jean-Pierre Roy
CSCéline Ster
Céline Ster
FMFrançois Malouin
François Malouin
Staphylococcus aureus causes intramammary infections (IMIs), which are refractory to antibiotic treatment and frequently result in chronic mastitis. IMIs are the leading cause of conventional antibiotic use in dairy farms. Phage therapy represents an alternative to antibiotics to help better manage mastitis in cows, reducing the global spread of resistance. A mouse mastitis model of S. aureus IMI was used to study the efficacy of a new cocktail of five lytic S. aureus-specific phages (StaphLyse™), administered either via the intramammary (IMAM) route or intravenously (IV). The StaphLyse™ phage cocktail was stable in milk for up to one day at 37 °C and up to one week at 4 °C. The phage cocktail was bactericidal in vitro against S. aureus in a dose-dependent manner. A single IMAM injection of this cocktail given 8 h after infection reduced the bacterial load in the mammary glands of lactating mice infected with S. aureus, and as expected, a two-dose regimen was more effective. Prophylactic use (4 h pre-challenge) of the phage cocktail was also effective, reducing S. aureus levels by 4 log10 CFU per gram of mammary gland. These results suggest that phage therapy may be a viable alternative to traditional antibiotics for the control of S. aureus IMIs.

17 June 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
GMGuillaume Millette
Guillaume Millette
DSDavid Lalonde Séguin
David Lalonde Séguin
CICharles Isabelle
Charles Isabelle
SCSuzanne Chamberland
Suzanne Chamberland
JLJean-Francois Lucier
Jean-Francois Lucier
FMFrançois Malouin
François Malouin
Prototypic Staphylococcus aureus and their small-colony variants (SCVs) are predominant in cystic fibrosis (CF), but the interdependence of these phenotypes is poorly understood. We characterized S. aureus isolates from adult CF patients over several years. Of 18 S. aureus-positive patients (58%), 13 (72%) were positive for SCVs. Characterization included genotyping, SCCmec types, auxotrophy, biofilm production, antibiotic susceptibilities and tolerance, and resistance acquisition rates. Whole-genome sequencing revealed that several patients were colonized with prototypical and SCV-related clones. Some clonal pairs showed acquisition of aminoglycoside resistance that was not explained by aminoglycoside-modifying enzymes, suggesting a mutation-based process. The characteristics of SCVs that could play a role in resistance acquisition were thus investigated further. For instance, SCV isolates produced more biofilm (p < 0.05) and showed a higher survival rate upon exposure to ciprofloxacin and vancomycin compared to their prototypic associated clones. SCVs also developed spontaneous rifampicin resistance mutations at a higher frequency. Accordingly, a laboratory-derived SCV (ΔhemB) acquired resistance to ciprofloxacin and gentamicin faster than its parent counterpart after serial passages in the presence of sub-inhibitory concentrations of antibiotics. These results suggest a role for SCVs in the establishment of persistent antibiotic-resistant clones in adult CF patients.

21 August 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
GMGuillaume Millette
Guillaume Millette
ELEvelyne Lacasse
Evelyne Lacasse
RBRenaud Binette
Renaud Binette
VBVéronique Belley
Véronique Belley
LCLouis-Philippe Chaumont
Louis-Philippe Chaumont
FMFrançois Malouin
François Malouin
Staphylococcus aureus is one of the major pathogens causing bovine mastitis, and antibiotic treatment is most often inefficient due to its virulence and antibiotic-resistance attributes. The development of new antibiotics for veterinary use should account for the One Health concept, in which humans, animals, and environmental wellbeing are all interconnected. S. aureus can infect cattle and humans alike and antibiotic resistance can impact both if the same classes of antibiotics are used. New effective antibiotic classes against S. aureus are thus needed in dairy farms. We previously described PC1 as a novel antibiotic, which binds the S. aureus guanine riboswitch and interrupts transcription of essential GMP synthesis genes. However, chemical instability of PC1 hindered its development, evaluation, and commercialization. Novel PC1 analogs with improved stability have now been rationally designed and synthesized, and their in vitro and in vivo activities have been evaluated. One of these novel compounds, PC206, remains stable in solution and demonstrates specific narrow-spectrum activity against S. aureus. It is active against biofilm-embedded S. aureus, its cytotoxicity profile is adequate, and in vivo tests in mice and cows show that it is effective and well tolerated. PC206 and structural analogs represent a promising new antibiotic class to treat S. aureus-induced bovine mastitis.

25 December 2025 in Nanoscale
Verified
Journal Article
Open access
PDF file
SMSatwik Majumder
Satwik Majumder
GMGuillaume Millette
Guillaume Millette
TSTrisha Sackey
Trisha Sackey
FMFrançois Malouin
François Malouin
Saji GeorgeSaji George
Saji George
Bovine mastitis (BM), resulting from intramammary infection, is one of the costliest diseases in animal agriculture. Nano-enabled Antibacterial Combination Therapy (NeACT) holds promise for BM treatment.